Pittsburgh, PANCT05877430Now EnrollingIRB Ready

Metastatic Cancer Clinical Trial in Pittsburgh, PA

Access cutting-edge metastatic cancer treatment through this clinical trial at a research site in Pittsburgh. Study-provided care at no cost to qualified participants.

Sponsored by CJ Bioscience, Inc.

Quick Self-Assessment

See if you qualify for this Pittsburgh location

Preparing your pre-screening questions...

Expert Care in Pittsburgh

Access metastatic cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metastatic cancer treatment provided free

Apply for This Pittsburgh Location

Check if you qualify for this metastatic cancer clinical trial in Pittsburgh, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Pittsburgh

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Pittsburgh site if eligible
  4. 4Begin participation

About This Metastatic Cancer Study in Pittsburgh

Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects with selected types of advanced or metastatic cancer. The proposed study intends to address the unmet medical needs of low response rate and refractoriness to immune checkpoint inhibitors typically observed in this subject population by performing assessments of response, dose limiting toxicities,

Sponsor: CJ Bioscience, Inc.

Who Can Participate

Inclusion Criteria

Willing and able to provide informed consent 2. ≥18 years of age at the time of signing the informed consent form 3. Pathologically documented histological or cytological evidence of NSCLC, HNSCC, or melanoma. 4. Has at least 1 measurable target lesion per RECIST v1.1 that has not been resected/biopsied/or irradiated before enrollment in the study 5. Diagnosis of locally advanced unresectable or metastatic NSCLC, HNSCC, or melanoma in subjects who are ICI treatment-naive or relapsed/refractory, including PD-1/PD-L1 inhibitors 6. ICI treatment-naive subjects must meet the following criteria: 1. NSCLC: Subjects with metastatic or with unresectable, recurrent NSCLC whose tumors must have no EGFR or ALK genomic aberrations and express PD-L1 \[TPS≥50%\] 2. HNSCC: Subjects with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 \[CPS ≥20\] 3. Melanoma: Irrespective of PD-L1 result and BRAF V600 mutation 4. Subjects has not receive

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Pittsburgh?

Yes, this clinical trial (NCT05877430) has an active research site in Pittsburgh, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Cancer Treatment Options in Pittsburgh, PA

If you're searching for metastatic cancer treatment options in Pittsburgh, PA, this clinical trial (NCT05877430) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Pittsburgh research site is actively enrolling participants for this clinical trial. You'll receive care from experienced metastatic cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic cancer clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Pittsburgh, PA

See all advanced solid tumors clinical trials recruiting in Pittsburgh — not just this study.

Browse Advanced Solid Tumors Trials in Pittsburgh →

Browse More Trials by Condition

Advanced Solid Tumors TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Pittsburgh?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Pittsburgh, PA